Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035100 · ClinicalTrials.gov registry record · Phase 2
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
A Phase 2 study of Ovarian Neoplasms and Peritoneal Neoplasms, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 8
- Study locations
NCT00035100 is a Phase 2 study of Ovarian Neoplasms and Peritoneal Neoplasms that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 54 participants, below the 366-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (85% lower). The trial reports 8 study locations across 4 states.
The verdict
NCT00035100, a Phase 2 study of Ovarian Neoplasms and Peritoneal Neoplasms, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the United States is complete but the study is still enrolling in other countries.
Conditions Studied
Interventions
- DRUG epothilone b
Study Locations (8)
Other
- Novartis Investigative Site - Amsterdam
- Novartis Investigative Site - Zwolle
- Novartis Investigative Site - Bratislava
- Novartis Investigative Site - Košice
- Novartis Investigative Site - Surrey
New Jersey
- Novartis Investigative Site - New Brunswick
Ontario
- Novartis Investigative Site - Toronto
Netherlands
- Novartis Investigative Site - Enschede
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2001-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035100
The ClinicalTrials.gov registry entry for NCT00035100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (85% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which epothilone b is the first listed.
NCT00035100 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Other, New Jersey, Ontario.
Frequently Asked Questions
What is clinical trial NCT00035100 about?
NCT00035100 is a clinical study titled "EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer". This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the United States is complete but t...
What is the current status of trial NCT00035100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2001-09.
What conditions does trial NCT00035100 study?
This clinical trial studies the following conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms.
What interventions are being tested in trial NCT00035100?
The interventions under investigation include: epothilone b (DRUG).
Who is sponsoring clinical trial NCT00035100?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00035100 being conducted?
This trial has 8 study locations across New Jersey, Ontario, Netherlands. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Vigil for Participants With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
COMPLETED · Phase 2
-
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.